Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 14/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 12/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 12/20 | 0.33 |
| ▸ | APAF1 | O14727 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109891 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| Bromide SCHEMBL2877682 | 0.99 | CHRM2 (0.36) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| Bromide SCHEMBL2877676 | 0.99 | CHRM2 (0.36) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL4783528 | 0.99 | LMNA (0.37) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL4739912 | 0.97 | LMNA (0.35) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL1109818 | 0.95 | CHRM2 (0.36) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL1109819 | 0.95 | CHRM2 (0.36) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL13329593 | 0.95 | HRH1 (0.38) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL4742969 | 0.95 | HRH1 (0.38) | CHRM2CHRM1KCNH2SLC6A3LMNA | |
| SCHEMBL13329581 | 0.95 | HRH1 (0.38) | CHRM2CHRM1KCNH2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | claimed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | claimed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | claimed |
| CN-101282949-A | Azole and thiazole derivatives and their use | ARGENTA DISCOVERY LTD (GB) | 2008-10-08 | — | — | CN | claimed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| CN-101282949-B | Azole and thiazole derivatives and uses thereof | ARGENTA DISCOVERY LTD | 2012-05-23 | — | — | CN | disclosed |
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| EP-2125728-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| CN-101282949-A | Azole and thiazole derivatives and their use | ARGENTA DISCOVERY LTD (GB) | 2008-10-08 | — | — | CN | disclosed |
| WO-2008103125-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | disclosed |
| EP-1924570-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885KCNH2 784/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | CHRM2 12/4885CHRM1 24/4885KCNH2 1470/4885 |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM1 2/4885KCNH2 425/4885 |
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | CCR1, CCR5, CCR3 | CHRM2 34/4885CHRM1 44/4885KCNH2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.